Header Logo

Connection

Naoko Takebe to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Naoko Takebe
Connection Strength
0.117
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  1. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903.
    View in: PubMed
    Score: 0.117
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.